Evaluating the effects of Umifenovir (Arbidol) in COVID-19
Phase 3
Recruiting
- Conditions
- COVID-19 pneumonia.COVID-19, virus identifiedU07.1
- Registration Number
- IRCT20151227025726N15
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Laboratory confirmed COVID-19 with RT-PCR
Oxygen saturation < 93%
Fever more than 72 hours before admission
Bilateral pulmonary infiltration
Age over 18 years old
Exclusion Criteria
Chronic kidney disease (Stage IV and V)
Acute kidney injury
Pregnancy or breastfeeding
Drug allergy history
Chronic liver disease (Child pugh C)
Mild phase of COVID-19
Critical phase of COVID-19
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fever. Timepoint: Daily. Method of measurement: Thermometer.;Cough. Timepoint: Daily. Method of measurement: Observation.;Dyspnea. Timepoint: Daily. Method of measurement: Observation.
- Secondary Outcome Measures
Name Time Method Hospitalization duration. Timepoint: At admission time and discharge time. Method of measurement: Clinical records.;Lung radiology changes. Timepoint: At admission time and seven and 14 days later. Method of measurement: Computed tomography.;Adverse drug reaction. Timepoint: Daily. Method of measurement: Observation.;Virological clearance. Timepoint: At admission time and seven and 14 days later. Method of measurement: Reverse transcription polymerase chain reaction.;Death. Timepoint: At the end of the study. Method of measurement: Medical record.;Need of mechanical ventilation. Timepoint: Daily. Method of measurement: Medical record.